Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amanjit Dhatt

Internal Medicine Reno, NV Medical Doctor

NPI 1811973795 CMS profile 218632

1495 Mill St, Reno, NV 89502

Open in the dashboard

General payments

$3,790

220 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanjit Dhatt of Reno, NV is reported in the CMS Open Payments database as having received $3,790 across 220 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $932 53
2024 General $555 38
2023 General $358 20
2022 General $286 12
2021 General $485 25
2020 General $225 16
2019 General $949 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanjit Dhatt
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Amanjit Dhatt were reported at $932. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Amanjit Dhatt Internal Medicine median Middle half National median
2019 $949 $159 $48–$570 $163
2020 $225 $119 $33–$402 $114
2021 $485 $135 $37–$521 $132
2022 $286 $141 $42–$496 $149
2023 $358 $149 $45–$519 $160
2024 $555 $154 $47–$537 $164
2025 $932 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $636 44 payments
  2. GlaxoSmithKline, LLC. $607 39 payments
  3. Regeneron Healthcare Solutions, Inc. $537 36 payments
  4. Genzyme Corporation $272 13 payments
  5. Pharming Healthcare, Inc. $228 8 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $172 13 payments
  7. CSL Behring $170 10 payments
  8. AstraZeneca Pharmaceuticals LP $148 9 payments
  9. Edwards Lifesciences Corporation $129 5 payments
  10. Octapharma USA, Inc. $128 6 payments
  11. Other $764 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,543 209 payments
  2. Education $208 8 payments
  3. Consulting Fee $39 3 payments
Products named General payments · program years 2019–2025
  1. HYQVIA $463 32 payments
  2. DUPIXENT Immunology $421 18 payments
  3. NUCALA $369 26 payments
  4. DUPIXENT Immunology And Inflammation $286 17 payments
  5. DUPIXENT Inflammation And Immunology $251 19 payments
  6. RUCONEST $228 8 payments
  7. SPIRIVA RESPIMAT $172 13 payments
  8. CUVITRU $160 11 payments
  9. SAPIEN 3 Ultra RESILIA $129 5 payments
  10. CUTAQUIG $128 6 payments
  11. Other $1,278 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,506

Median for Internal Medicine: 777

Drug cost

$427,107

Median for Internal Medicine: $73,373

Branded share of claims

58.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 23 $97,645
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 277 $81,371
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 279 $56,075
Xolair Omalizumab Brand 15 $43,996
Dupixent Syringe Dupilumab Brand 11 $39,961
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 44 $36,843
Spiriva Respimat Tiotropium Bromide Brand 15 $13,469
Arnuity Ellipta Fluticasone Furoate Brand 34 $12,358
Epinephrine Generic 58 $9,689
Breo Ellipta Fluticasone/Vilanterol Brand 12 $7,752

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$114,148

Medicare's payments for the services billed

Medicare patients

234

Average age 73

Services billed

11,471

172 women, 62 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 50%
Depression 23%
Ischemic heart disease 20%
Osteoporosis 19%
Chronic kidney disease 15%
COPD 13%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$188 11 —
HYQVIA
$144 — —
TRELEGY ELLIPTA
$58 44 —
Hizentra
$32 23 —
CUTAQUIG
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record